DrugPatentWatch Database Preview
Drugs in Development Information for Veledimex
What is the development status for investigational drug Veledimex?
Veledimex is an investigational drug.
There have been 8 clinical trials for Veledimex.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 28th 2019.
The most common disease conditions in clinical trials are Glioblastoma, Breast Neoplasms, and Scleroderma, Systemic. The leading clinical trial sponsors are Ziopharm, Fibrocell Technologies, Inc., and [disabled in preview].
There are eighteen US patents protecting this investigational drug and one hundred and eighty-four international patents.
Summary for Veledimex
| US Patents | 18 |
| International Patents | 184 |
| US Patent Applications | 44 |
| WIPO Patent Applications | 13 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2019-06-28) |
| Vendors | 9 |
Recent Clinical Trials for Veledimex
| Title | Sponsor | Phase |
|---|---|---|
| Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma | Ziopharm | Phase 2 |
| A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma | Fibrocell Technologies, Inc. | Phase 1/Phase 2 |
| Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 | Ziopharm | Phase 1 |
Clinical Trial Summary for Veledimex
Top disease conditions for Veledimex
Top clinical trial sponsors for Veledimex
US Patents for Veledimex
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Veledimex | Start Trial | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| Veledimex | Start Trial | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| Veledimex | Start Trial | Process of preparing chiral diacylhydrazine ligands | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| Veledimex | Start Trial | Modified forms of Pseudomonas exotoxin A | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| Veledimex | Start Trial | Crystalline diacylhydrazine and the use thereof | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| Veledimex | Start Trial | Boron-containing diacylhydrazines | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| Veledimex | Start Trial | Methods and compositions for diagnosing disease | Intrexon Corporation (Blacksburg, VA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Veledimex
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Veledimex | Australia | 2008307643 | 2027-09-28 | Start Trial |
| Veledimex | Brazil | PI0817233 | 2027-09-28 | Start Trial |
| Veledimex | Canada | 2715080 | 2027-09-28 | Start Trial |
| Veledimex | China | 101868241 | 2027-09-28 | Start Trial |
| Veledimex | European Patent Office | 2205249 | 2027-09-28 | Start Trial |
| Veledimex | Israel | 204731 | 2027-09-28 | Start Trial |
| Veledimex | Japan | 2010540534 | 2027-09-28 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
